AzTrials
AzTrials

Relapsed or Refractory Multiple MyelomaPhase 3SUCCESSOR-1NCT05519085

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3 study testing mezigdomide, Pomalidomide and Bortezomib in people with Relapsed or Refractory Multiple Myeloma, run by Celgene at 266 sites in 29 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Relapsed or Refractory Multiple Myeloma
What is being tested?
mezigdomide, Pomalidomide and Bortezomib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
810 participants
Where
266 sitesin 29 countries
Study dates
20 Sep 2022to 30 Nov 2033
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.
  • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.
  • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).
  • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
  • Participants received 1 to 3 prior lines of antimyeloma therapy.
  • Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

Who cannot join

  • Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:.
  • Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded.
  • Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded.
  • For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
  • Participant has had prior treatment with mezigdomide or pomalidomide.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

266 sites in 29 countries. Contact the study team or a site near you to ask about taking part.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #. contact

266 sites in 29 countries

United States56 sites, 3 recruiting

  • Local Institution - 0378

    Abilene, Texas, 79606

    Completed

  • Local Institution - 0302

    Albuquerque, New Mexico, 87131

    Active, not recruiting

  • Local Institution - 0359

    Allentown, Pennsylvania, 18103

    Completed

  • Local Institution - 0271

    Ann Arbor, Michigan, 48109

    Active, not recruiting

  • Local Institution - 0211

    Athens, Georgia, 30607

    Active, not recruiting

  • Local Institution - 0381

    Aurora, Colorado, 80045

    Site 0381

    Not yet recruiting

  • Local Institution - 0357

    Baltimore, Maryland, 21215

    Completed

  • Local Institution - 0358

    Baton Rouge, Louisiana, 70808

    Active, not recruiting

  • Local Institution - 0246

    Boston, Massachusetts, 02215

    Active, not recruiting

  • Local Institution - 0245

    Buffalo, New York, 14215

    Withdrawn

  • Local Institution - 0400

    Cincinnati, Ohio, 45242

    Completed

  • Local Institution - 0377

    Cleveland, Ohio, 44111

    Active, not recruiting

  • Local Institution - 0076

    Cleveland, Ohio, 44195

    Active, not recruiting

  • Local Institution - 0303

    Coral Springs, Florida, 33321

    Active, not recruiting

  • Local Institution - 0364

    Detroit, Michigan, 48202

    Completed

  • Local Institution - 0260

    Durham, North Carolina, 27710

    Active, not recruiting

  • Local Institution - 0288

    East Brunswick, New Jersey, 08816

    Active, not recruiting

  • Local Institution - 0380

    Farmington, Connecticut, 06030

    Completed

  • Local Institution - 0403

    Fort Myers, Florida, 33901

    Completed

  • Local Institution - 0297

    Fredericksburg, Virginia, 22408

    Active, not recruiting

  • Local Institution - 0330

    Garden City, Kansas, 67846

    Completed

  • Local Institution - 0223

    Germantown, Tennessee, 38138

    Active, not recruiting

  • Local Institution - 0088

    Hattiesburg, Mississippi, 39401

    Active, not recruiting

  • Local Institution - 0275

    Houston, Texas, 77030

    Active, not recruiting

  • Local Institution - 0242

    Jackson, Mississippi, 39213

    Withdrawn

  • Local Institution - 0257

    Lake Success, New York, 11042

    Active, not recruiting

  • Local Institution - 0366

    Los Alamitos, California, 90720

    Active, not recruiting

  • Local Institution - 0220

    Madison, Wisconsin, 53792

    Withdrawn

  • Local Institution - 0048

    Marietta, Georgia, 30060

    Withdrawn

  • Local Institution - 0376

    Mayfield Heights, Ohio, 44124

    Completed

  • Local Institution - 0410

    Minneapolis, Minnesota, 55404

    Active, not recruiting

  • Local Institution - 0208

    New Haven, Connecticut, 06510

    Withdrawn

  • Local Institution - 0373

    New Hyde Park, New York, 11042

    Completed

  • Local Institution - 0255

    New Orleans, Louisiana, 70112

    Active, not recruiting

  • Local Institution - 0371

    New York, New York, 10028

    Completed

  • Local Institution - 0408

    Norfolk, Virginia, 23502

    Active, not recruiting

  • Local Institution - 0401

    Orange City, Florida, 32763

    Active, not recruiting

  • Local Institution - 0363

    Ridgewood, New Jersey, 07450

    Site 0363

    Not yet recruiting

  • Local Institution - 0399

    Roanoke, Virginia, 24014

    Completed

  • Local Institution - 0108

    Rochester, New York, 14621

    Active, not recruiting

  • Local Institution - 0207

    Salt Lake City, Utah, 84106

    Completed

  • Local Institution - 0267

    San Antonio, Texas, 78229

    Active, not recruiting

  • Local Institution - 0409

    San Antonio, Texas, 78240

    Active, not recruiting

  • Local Institution - 0272

    San Diego, California, 92123

    Completed

  • Local Institution - 0268

    Seattle, Washington, 98108

    Active, not recruiting

  • Local Institution - 0293

    Seattle, Washington, 98109

    Withdrawn

  • Local Institution - 0374

    Shirley, New York, 11967

    Completed

  • Local Institution - 0385

    Shreveport, Louisiana, 71103

    Site 0385

    Not yet recruiting

  • Local Institution - 0097

    Spokane, Washington, 99208

    Withdrawn

  • Local Institution - 0372

    The Bronx, New York, 10469

    Completed

  • Local Institution - 0411

    Vancouver, Washington, 98684

    Completed

  • Local Institution - 0273

    West Hollywood, California, 90069

    Completed

  • Local Institution - 0402

    West Palm Beach, Florida, 33401

    Active, not recruiting

  • Local Institution - 0080

    Westwood, Kansas, 66205

    Active, not recruiting

  • Local Institution - 0274

    Williamsville, New York, 14221

    Withdrawn

  • Local Institution - 0264

    York, Pennsylvania, 17403

    Completed

Other trials in United States

China36 sites, 2 recruiting

  • Local Institution - 0062

    Beijing, Beijing Municipality, 100043

    Active, not recruiting

  • Local Institution - 0165

    Beijing, Beijing Municipality, 100043

    Completed

  • Local Institution - 0141

    Beijing, Beijing Municipality, 100091

    Completed

  • Local Institution - 0150

    Beijing, 100034

    Completed

  • Local Institution - 0155

    Changsha, Hunan, 410008

    Active, not recruiting

  • Local Institution - 0147

    Changsha, Hunan, 410013

    Active, not recruiting

  • Local Institution - 0144

    Chongqing, Chongqing Municipality, 400016

    Active, not recruiting

  • Local Institution - 0356

    Deyang, Sichuan, 618000

    Site 0356

    Not yet recruiting

  • Local Institution - 0117

    Guangzhou, Guangdong, 450008

    Active, not recruiting

  • Local Institution - 0177

    Guangzhou, Guangdong, 510060

    Active, not recruiting

  • Local Institution - 0168

    Guangzhou, Guangdong, 510080

    Withdrawn

  • Local Institution - 0151

    Hangzhou, Zhejiang, 310003

    Withdrawn

  • Local Institution - 0202

    Kunming, Yunnan, 650032

    Active, not recruiting

  • Local Institution - 0348

    Linhai, Zhejiang, 317000

    Active, not recruiting

  • Local Institution - 0412

    Liuzhou, Guangxi, 0

    Completed

  • Local Institution - 0395

    Luoyang, Henan, 471003

    Completed

  • Local Institution - 0111

    Nanjing, Jiangsu, 210000

    Active, not recruiting

  • Local Institution - 0240

    Nanning, Guangxi, 530007

    Active, not recruiting

  • Local Institution - 0112

    Ningbo, Zhejiang, 315010

    Active, not recruiting

  • Local Institution - 0169

    Qingdao, Shandong, 266000

    Completed

  • Local Institution - 0114

    Shanghai, Shanghai Municipality, 200030

    Active, not recruiting

  • Local Institution - 0350

    Shanghai, Shanghai Municipality, 200434

    Active, not recruiting

  • Local Institution - 0287

    Shenyang, Liaoning, 110004

    Active, not recruiting

  • Local Institution - 0238

    Shenzhen, Guangdong, 518039

    Active, not recruiting

  • Local Institution - 0254

    Shijiazhuang, Hebei, 50000

    Active, not recruiting

  • Local Institution - 0164

    Taiyuan, Shanxi, 030001

    Active, not recruiting

  • Local Institution - 0176

    Taiyuan, 030032

    Active, not recruiting

  • Local Institution - 0119

    Tianjin, Tianjin Municipality, 300060

    Active, not recruiting

  • Local Institution - 0353

    Ürümqi, Xinjiang, 830001

    Site 0353

    Not yet recruiting

  • Local Institution - 0149

    Wenzhou, Zhejiang, 32500

    Active, not recruiting

  • Local Institution - 0142

    Wuhan, Hubei, 430022

    Active, not recruiting

  • Local Institution - 0139

    Wuxi, Jiangsu, 214023

    Active, not recruiting

  • Local Institution - 0148

    Xi'an, Shaanxi, 710004

    Active, not recruiting

  • Local Institution - 0110

    Xi'an, Shaanxi, 710126

    Completed

  • Local Institution - 0237

    Xiamen, Fujian, 361003

    Active, not recruiting

  • Local Institution - 0113

    Zhengzhou, Henan, 450003

    Active, not recruiting

Other trials in China

Japan18 sites

  • Local Institution - 0279

    Chiba, 260-8677

    Active, not recruiting

  • Local Institution - 0286

    Fukuoka, 810-8563

    Active, not recruiting

  • Local Institution - 0295

    Fukuoka, 815-8555

    Active, not recruiting

  • Local Institution - 0417

    Higashiibaraki, Ibaraki, 3113117

    Completed

  • Local Institution - 0291

    Hiroshima, 730-8619

    Active, not recruiting

  • Local Institution - 0290

    Iruma, Saitama, 350-0495

    Active, not recruiting

  • Local Institution - 0294

    Kamakura, Kanagawa, 247-8533

    Active, not recruiting

  • Local Institution - 0281

    Kashiwa, Chiba, 277-8577

    Active, not recruiting

  • Local Institution - 0278

    Kitakyushu-shi, Fukuoka, 806-8501

    Active, not recruiting

  • Local Institution - 0285

    Koshigaya, Saitama, 3438555

    Active, not recruiting

  • Local Institution - 0284

    Kumamoto, 860-8556

    Active, not recruiting

  • Local Institution - 0289

    Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777

    Active, not recruiting

  • Local Institution - 0277

    Nagasaki, 852-8511

    Active, not recruiting

  • Local Institution - 0280

    Sapporo, Hokkaido, 003-0804

    Active, not recruiting

  • Local Institution - 0283

    Shibuya-ku, Tokyo, 150-8935

    Active, not recruiting

  • Local Institution - 0276

    Shiwa-gun Yahaba-cho, Iwate, 028-3695

    Active, not recruiting

  • Local Institution - 0296

    tabashi City, Tokyo, 173-8610

    Active, not recruiting

  • Local Institution - 0300

    Tokyo, 105-000

    Active, not recruiting

Other trials in Japan

Germany16 sites, 16 recruiting

  • Universitätsklinikum Aachen

    Aachen, 52074

    Deniz Gezer, Site 0391, +49492418089770

    Recruiting

  • Sozialstiftung Bamberg

    Bamberg, 96049

    Christof Schweizer, Site 0390, 004995150313713

    Recruiting

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127

    Sebastian Schlaweck, Site 0092, 022828717000

    Recruiting

  • Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf

    Dresden, 01307

    Thomas Illmer, Site 0413, 00493514400022

    Recruiting

  • Marien Hospital Düsseldorf

    Düsseldorf, North Rhine-Westphalia, 40479

    Maika Klaiber-Hakimi, Site 0415, 021144006629

    Recruiting

  • Local Institution - 0396

    Erfurt, Thuringia, 99085

    Site 0396

    Not yet recruiting

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, 20251

    Katja Weisel, Site 0015, 4940741058787

    Recruiting

  • Asklepios Altona

    Hamburg, 22763

    Hans-Jürgen Salwender, Site 0388, 49-40-181881-1273

    Recruiting

  • Praxis Onkologie am Raschplatz

    Hanover, Lower Saxony, 30161

    Eyck von der Heyde, Site 0414, 0177-6506614

    Recruiting

  • Universitaetsklinikum Schleswig-Holstein Campus Kiel

    Kiel, Schleswig-Holstein, 24105

    Natalie Schub, Site 0058, +49 431 500 22711

    Recruiting

  • Universitaetsklinik Marburg

    Marburg, Hesse, 35033

    Christoph Mann, Site 0059, 064215861413

    Recruiting

  • TUM Klinikum

    München, Bavaria, 81675

    Marion Hoegner, Site 0392, 498941405907

    Recruiting

  • Klinikum Traunstein

    Traunstein, Bavaria, 83278

    Matthias Egger, Site 0397, 00498617052595

    Recruiting

  • Universitaetsklinikum Tuebingen

    Tübingen, 72076

    Britta Besemer, Site 0010, 4970712982711

    Recruiting

  • Medizinisches Versorgungszentrum

    Weiden, Bavaria, 92367

    Thomas Schichtl, Site 0393, +4930313660

    Recruiting

  • Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher

    Würzburg, 97080

    Dominik Pretscher, Site 0394, 0049931322670

    Recruiting

Other trials in Germany

South Korea16 sites, 9 recruiting

  • Local Institution - 0106

    Busan, Busan, 49241

    Withdrawn

  • Pusan National University Hospital

    Busan, Busan, 49241

    Ho-Jin Shin, Site 0087, 821089371258

    Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeonranamdo, 58128

    Sung Hoon Jung, Site 0085, 82613797623

    Recruiting

  • Local Institution - 0103

    Hwasun, Jeonranamdo, 58128

    Withdrawn

  • Local Institution - 0102

    Seongnam, Gyeonggido, 13620

    Withdrawn

  • Seoul National University Bundang Hospital

    Seongnam, Gyeonggido, 13620

    Ji Yun Lee, Site 0086, 82-10-6223-5401

    Recruiting

  • Local Institution - 0101

    Seoul, Seoul Teugbyeolsi, 03080

    Withdrawn

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080

    Ja Min Byun, Site 0081, 821071243234

    Recruiting

  • Samsung Medical Center

    Seoul, Seoul Teugbyeolsi, 06351

    Kihyun Kim, Site 0083, +821099333456

    Recruiting

  • Local Institution - 0104

    Seoul, Seoul Teugbyeolsi, 06591

    Withdrawn

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    Seoul, Seoul Teugbyeolsi, 06591

    Chang Ki Min, Site 0084, 82-20-2258-6053

    Recruiting

  • Asan Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], 05505

    Dok Hyun Yoon, Site 0258, 82230105940

    Recruiting

  • Local Institution - 0105

    Seoul, Seoul-teukbyeolsi, 05505

    Withdrawn

  • Local Institution - 0100

    Seoul, 03722

    Withdrawn

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

    Jin Seok Kim, Site 0090, 82222281972

    Recruiting

  • Local Institution

    Seoul, 138-736

    Site 0082

    Not yet recruiting

Other trials in South Korea

France10 sites

  • Local Institution - 0116

    Clermont-Ferrand, 63100

    Active, not recruiting

  • Local Institution - 0146

    Lille, Nord, 59000

    Active, not recruiting

  • Local Institution - 0167

    Limoges, 87042

    Active, not recruiting

  • Local Institution - 0205

    Lyon Cedex08, Auvergne-Rhône-Alpes, 69373

    Active, not recruiting

  • Local Institution - 0043

    Nantes, 44093

    Completed

  • Local Institution - 0216

    Nîmes, 30029

    Active, not recruiting

  • Local Institution - 0115

    Paris, Île-de-France Region, 75571

    Completed

  • Local Institution - 0091

    Pessac, Aquitaine, 33600

    Active, not recruiting

  • Local Institution - 0175

    Strasbourg, 67098

    Active, not recruiting

  • Local Institution - 0188

    Tours, 37032

    Active, not recruiting

Other trials in France

Spain10 sites

  • Local Institution - 0073

    Barcelona, Catalunya [Cataluña], 08036

    Withdrawn

  • Local Institution - 0210

    Barcelona, Catalunya [Cataluña], 08036

    Active, not recruiting

  • Local Institution - 0328

    Cáceres, 10003

    Active, not recruiting

  • Local Institution - 0074

    León, 24071

    Active, not recruiting

  • Local Institution - 0181

    Madrid, 28041

    Active, not recruiting

  • Local Institution - 0182

    Marbella, Málaga, 29603

    Withdrawn

  • Local Institution - 0253

    Marbella, Málaga, 29603

    Active, not recruiting

  • Local Institution - 0075

    Murcia, Murcia, Región de, 30008

    Active, not recruiting

  • Local Institution - 0183

    Palma, Balearic Islands, 07120

    Withdrawn

  • Local Institution - 0252

    Palma, Balears [Baleares], 07120

    Active, not recruiting

Other trials in Spain

United Kingdom9 sites, 9 recruiting

  • Lanarkshire NHS Trust - Monklands Hospital

    Airdrie, Lanarkshire, ML6 0JS

    Iain Singer, Site 0127, 01236 712754

    Recruiting

  • Barnet Hospital

    Barnet, EN5 3DJ

    Huw Richards, Site 0304, 0208 216 4925

    Recruiting

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, CB2 0QQ

    Marquita Camilleri, Site 0326, 44(0) 1223 596297

    Recruiting

  • Leicester Royal Infirmary

    Leicester, Leicestershire, LE1 5WW

    Shelina Sachedina, Site 0131, 01162586617

    Recruiting

  • King's College Hospital

    London, Greater London, SE5 9RS

    Kirsty Cuthill, Site 0128, 44 (0) 20 3299 5501

    Recruiting

  • Hammersmith Hospital

    London, London, City of, W12 0HS

    Aristeidis Chaidos, Site 0367, 02033133236

    Recruiting

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN

    Jennifer Young, Site 0124, 01912336161

    Recruiting

  • Royal Stoke University Hospital

    Stoke-on-Trent, ST4 6QG

    Kamaraj Karunanithi, Site 0217, +441782674285

    Recruiting

  • The Royal Cornwall Hospital

    Truro, England, TR1 3LJ

    Adam Forbes, Site 0218, 01872252765

    Recruiting

Other trials in United Kingdom

Australia8 sites

  • Local Institution - 0327

    Birtinya, Queensland, 4575

    Active, not recruiting

  • Local Institution - 0221

    Box Hill, Victoria, 3128

    Active, not recruiting

  • Local Institution - 0055

    Liverpool, New South Wales, 2170

    Active, not recruiting

  • Local Institution - 0003

    Melbourne, Victoria, 3004

    Active, not recruiting

  • Local Institution - 0002

    Melbourne, Victoria, 3065

    Active, not recruiting

  • Local Institution - 0040

    Nedlands, Western Australia, 6009

    Active, not recruiting

  • Local Institution - 0004

    Waratah, New South Wales, 2298

    Active, not recruiting

  • Local Institution - 0017

    Wollongong, New South Wales, 2500

    Active, not recruiting

Other trials in Australia

India8 sites, 6 recruiting

  • HCG Aastha Cancer Centre

    Ahmedabad, Gujarat, 380060

    Abhishek Dudhatra, Site 0342, 9978115559

    Recruiting

  • KLES Dr. Prabhakar Kore Hospital & M.R.C

    Belagavi, Karnataka, 590010

    Rohan Bhise, Site 0336, 09448866712

    Recruiting

  • Marengo Asia Hospitals Gurugram

    Gurugram, Haryana, 122011

    Meet Kumar, Site 0338, 09038791250

    Recruiting

  • Christian Medical College & Hospital

    Ludhiana, 141008

    M Joseph John, Site 0343, 8054959525

    Recruiting

  • Local Institution - 0344

    Madurai, Tamil Nadu, 625107

    Completed

  • Mumbai Oncocare Centre - Nanachowk

    Mumbai, Maharashtra, 400036

    Udip Maheshwari, Site 0416, 7677434237

    Recruiting

  • Jawaharlal Institute Of Postgraduate Medical Education And Research

    Puducherry, 605006

    Biswajit Dubashi, Site 0345, 8056338305

    Recruiting

  • Local Institution - 0341

    Varanasi, Uttar Pradesh, 221002

    Completed

Other trials in India

Argentina7 sites

  • Local Institution - 0213

    Buenos Aires, Buenos Aires F.D., 1425

    Active, not recruiting

  • Local Institution - 0214

    Buenos Aires, CP1280AEB

    Active, not recruiting

  • Local Institution - 0318

    Chivilcoy, Buenos Aires, 6620

    Active, not recruiting

  • Local Institution - 0249

    Córdoba, Córdoba Province, 5016

    Active, not recruiting

  • Local Institution - 0200

    Rosario, Santa Fe Province, 2000

    Active, not recruiting

  • Local Institution - 0248

    S3000epv, Santa Fe Province, 3000

    Completed

  • Local Institution - 0239

    Viedma, R, R8500ACE

    Active, not recruiting

Other trials in Argentina

Brazil7 sites

  • Local Institution - 0305

    Jaú, São Paulo, 17210-080

    Active, not recruiting

  • Local Institution - 0314

    Joinville, Santa Catarina, 89201260

    Active, not recruiting

  • Local Institution - 0044

    Porto Alegre, Rio Grande do Sul, 90110-270

    Active, not recruiting

  • Local Institution - 0049

    Rio de Janeiro, 22793080

    Active, not recruiting

  • Local Institution - 0046

    Salvador, Estado de Bahia, 40301-155

    Active, not recruiting

  • Local Institution - 0050

    São Paulo, 04537-080

    Active, not recruiting

  • Local Institution - 0045

    São Paulo, 05652-900

    Active, not recruiting

Other trials in Brazil

Israel6 sites

  • Local Institution - 0192

    Haifa, Northern District, 3109601

    Active, not recruiting

  • Local Institution - 0197

    Jerusalem, Jerusalem, 91220

    Active, not recruiting

  • Local Institution - 0196

    Kfar Saba, Central District, 4428164

    Active, not recruiting

  • Local Institution - 0194

    Peatch Tikva, 49100

    Active, not recruiting

  • Local Institution - 0195

    Ramat Gan, Central District, 5262100

    Active, not recruiting

  • Local Institution - 0193

    Tel Aviv, Tall Abīb, 6423906

    Active, not recruiting

Other trials in Israel

Poland6 sites, 1 recruiting

  • Local Institution - 0185

    Katowice, 40-519

    Active, not recruiting

  • Local Institution - 0325

    Krakow, Lesser Poland Voivodeship, 30-727

    Site 0325

    Not yet recruiting

  • Local Institution - 0346

    Skórzewo, Greater Poland Voivodeship, 60-185

    Withdrawn

  • Local Institution - 0292

    Słupsk, Pomeranian Voivodeship, 76-200

    Completed

  • Local Institution - 0224

    Torun, Kuyavian-Pomeranian Voivodeship, 87-100

    Completed

  • Local Institution - 0250

    Warsaw, Masovian Voivodeship, 02-776

    Completed

Other trials in Poland

Turkey (Türkiye)6 sites

  • Local Institution - 0232

    Ankara, 06620

    Active, not recruiting

  • Local Institution - 0339

    Ankara, 06680

    Active, not recruiting

  • Local Institution - 0228

    Istanbul, 34093

    Active, not recruiting

  • Local Institution - 0229

    Izmir, 35100

    Active, not recruiting

  • Local Institution - 0226

    Kayseri, 0

    Active, not recruiting

  • Local Institution - 0227

    Samsun, 55139

    Active, not recruiting

Other trials in Turkey (Türkiye)

Austria5 sites

  • Local Institution - 0008

    Krems, 3500

    Active, not recruiting

  • Local Institution - 0024

    Leoben, 8700

    Completed

  • Local Institution - 0011

    Sankt Pölten, 3100

    Active, not recruiting

  • Local Institution - 0012

    Vienna, State of Vienna, 1160

    Active, not recruiting

  • Local Institution - 0025

    Vienna, 1140

    Active, not recruiting

Other trials in Austria

Italy5 sites

  • Local Institution - 0159

    Bologna, 40138

    Active, not recruiting

  • Local Institution - 0160

    Catania, Sicily, 95123

    Active, not recruiting

  • Local Institution - 0384

    Meldola, Emilia-Romagna, 47014

    Active, not recruiting

  • Local Institution - 0158

    Pavia, 27100

    Active, not recruiting

  • Local Institution - 0212

    Rome, Roma, 00189

    Active, not recruiting

Other trials in Italy

Belgium4 sites

  • Local Institution - 0136

    Antwerp, 2030

    Active, not recruiting

  • Local Institution - 0138

    Genk, Limburg, 3600

    Completed

  • Local Institution - 0206

    Ghent, Oost-Vlaanderen, 9000

    Active, not recruiting

  • Local Institution - 0179

    Sint-Niklaas, Oost-Vlaanderen, B-9100

    Completed

Other trials in Belgium

Ireland4 sites

  • Local Institution - 0122

    Cork, T12 E8YV

    Active, not recruiting

  • Local Institution - 0120

    Dublin, D08 E9P6

    Active, not recruiting

  • Local Institution - 0121

    Galway, Connacht, H91 YR71

    Active, not recruiting

  • Local Institution - 0251

    Limerick, V94 F858

    Withdrawn

Other trials in Ireland

New Zealand4 sites

  • Local Institution - 0369

    Auckland, 1023

    Active, not recruiting

  • Local Institution - 0334

    Auckland, 2025

    Withdrawn

  • Local Institution - 0340

    Dunedin, Otago, 9016

    Active, not recruiting

  • Local Institution - 0335

    Tauranga, Bay of Plenty, 3112

    Active, not recruiting

Other trials in New Zealand

South Africa4 sites

  • Local Institution - 0404

    Cape Town, Western Cape, 7925

    Active, not recruiting

  • Local Institution - 0405

    Centurion, GP, 0044

    Active, not recruiting

  • Local Institution - 0407

    Kuilsriver, Western Cape, 7580

    Active, not recruiting

  • Local Institution - 0406

    Plumstead, Western Cape, 7800

    Active, not recruiting

Other trials in South Africa

Canada3 sites

  • Local Institution - 0225

    Greenfield Park, Quebec, J4V 2H1

    Active, not recruiting

  • Local Institution - 0174

    Montreal, Quebec, H4J 1C5

    Active, not recruiting

  • Local Institution - 0222

    Québec, Quebec, G1J 1Z4

    Active, not recruiting

Other trials in Canada

Chile3 sites

  • Local Institution - 0329

    Santiago, Santiago Metropolitan, 7580206

    Active, not recruiting

  • Local Institution - 0387

    Santiago, Santiago Metropolitan, 8420383

    Active, not recruiting

  • Local Institution - 0332

    Viña del Mar, Valparaiso, 0

    Active, not recruiting

Other trials in Chile

Czechia3 sites

  • Local Institution - 0037

    Brno, Brno-město, 625 00

    Active, not recruiting

  • Local Institution - 0383

    Prague, Praha 10, 100 34

    Completed

  • Local Institution - 0039

    Prague, 12808

    Active, not recruiting

Other trials in Czechia

Greece3 sites, 1 recruiting

  • Local Institution - 0190

    Athens, Attikí, 106 76

    Active, not recruiting

  • Local Institution - 0191

    Athens, Attikí, 115 28

    Active, not recruiting

  • G. Papanikolaou General Hospital

    Thessaloniki, Thessaloníki, 570 10

    Ioanna Sakellari, Site 0189, 302313307550

    Recruiting

Other trials in Greece

Portugal3 sites, 3 recruiting

  • Hospital de Braga

    Braga, 4710-243

    Rita Gomes, Site 0056

    Recruiting

  • Champalimaud Foundation

    Lisbon, 1400-038

    Cristina João, Site 0014

    Recruiting

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE

    Porto, 4200-072

    Angelo Martins, Site 0301, 351225084000

    Recruiting

Other trials in Portugal

Romania3 sites

  • Local Institution - 0021

    Bucharest, 022328

    Active, not recruiting

  • Local Institution - 0052

    Cluj-Napoca, 400124

    Active, not recruiting

  • Local Institution - 0035

    Iași, 700483

    Active, not recruiting

Other trials in Romania

Finland2 sites

  • Local Institution - 0072

    Helsinki, 00029

    Active, not recruiting

  • Local Institution - 0256

    Kuopio, Northern Savonia, 70210

    Active, not recruiting

Other trials in Finland

Puerto Rico1 site

  • Local Institution - 0355

    San Juan, 00909

    Withdrawn

Other trials in Puerto Rico

About this study

Official title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Being tested
mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
Keywords
Multiple myeloma, RRMM, MeziVd, PVd, CC92480, pomalidomide, bortezomib, dexamethasone, mezigdomide
Medical subject headings
Recurrence, Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • mezigdomideDrug

    Also called BMS-986348, CC-92480

    Specified dose on specified days

  • PomalidomideDrug

    Also called Pomalyst, Imnovid, Pom

    Specified dose on specified days

  • BortezomibDrug

    Also called Velcade, BTZ

    Specified dose on specified days

  • DexamethasoneDrug

    Also called Decadron, Dex

    Specified dose on specified days

Study groups in NCT05519085
Study groupRoleWhat they receive
MeziVd (mezigdomide, bortezomib and dexamethasone)ExperimentalNot described
Receives: Drug: mezigdomide; Drug: Bortezomib; Drug: Dexamethasone
PVd (pomalidomide, bortezomib and dexamethasone)ExperimentalNot described
Receives: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free Survival (PFS)

    Measured: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)

Secondary outcomes (15)

  1. Recommended mezigdomide dose

    Stage 1 only

    Measured: Up to 12 Months

  2. Plasma concentrations of mezigdomide

    Stage 1 only

    Measured: Up to 134 Days

  3. Overall Survival (OS)

    Measured: From date of randomization to date of death due to any cause (Up to approximately 5 years)

  4. Overall Response (OR)

    OR is defined as the number of participants who achieve best response of partial response (PR) or better according to the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma

    Measured: Up to approximately 5 years

  5. Complete Response (CR) or better

    Defined as the number of participants who achieve best response of complete response (CR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

    Measured: Up to approximately 5 Years

  6. Very Good Partial Response (VGPR) or better

    Defined as the number of participants who achieve best response of very good partial response (VGPR) or better according to the IMWG Uniform Response Criteria for Multiple Myeloma

    Measured: Up to approximately 5 years

  7. Time to Response (TTR)

    Measured: Up to approximately 5 years

  8. Duration of Response (DOR)

    Measured: Up to approximately 5 years

  9. Time to Progression (TTP)

    Measured: Up to approximately 5 years

  10. Time to Next Treatment (TTNT)

    Measured: Up to approximately 5 years

  11. Progression-free Survival 2 (PFS-2)

    Measured: Up to approximately 5 years

  12. Minimal Residual Disease (MRD) negativity

    Defined as the number of participants who achieve complete response (CR) or better and MRD negativity (defined as less than 1 in 10^5 nucleated cells [by next generation flow cytometry] in bone marrow aspirate)

    Measured: Up to approximately 5 years

  13. Number of participants with Adverse Events (AEs)

    Measured: Up to approximately 5 years

  14. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores

    The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

    Measured: Up to approximately 5 years

  15. Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score

    The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

    Measured: Up to approximately 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2022
  2. Study start20 Sep 2022
  3. Primary completion10 Jan 2027 (estimated)
  4. Study completion30 Nov 2033 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
810 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05519085
Sponsor's protocol ID
CA057-001
Other IDs
2023-509859-13, 2023
Acronym
SUCCESSOR-1
Status last verified
Oct 2026
First submitted
25 Aug 2022
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing mezigdomide, Pomalidomide and Bortezomib in people with Relapsed or Refractory Multiple Myeloma, run by Celgene at 266 sites in 29 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 266 sites in United States, China, Japan, Germany, South Korea and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com (855-907-3286, Clinical.Trials@bms.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free Survival (PFS) (time frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05519085.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in